Plus   Neg

Stock Alert: United Natural Foods Gains 10% On Quarterly Results

Shares of food distributor United Natural Foods, Inc. (UNFI) are climbing more than 10% on the back of better-than estimated second-quarter earnings. The sock is currently trading at $7.49. It has traded in the range of $5.00- $14.44 in the last 52-weeks.

Net loss for the second quarter was $31 million or $0.57 per share, narrower than $342 million or $6.72 per share loss in the same quarter a year ago. Last year's second quarter included a $370.9 million pre-tax goodwill impairment charge as well as $17.4 million in additional restructuring, acquisition, and integration-related expenses.

Excluding items, earnings were down at $0.32 per share impacted by charges associated with three customer bankruptcies. This compares with $0.44 per share last year. On average, 8 analysts polled by Thomson Reuters were expecting earnings of $0.27.

Net Sales were $6.138 billion compared to $6.149 billion in last year's quarter. The consensus estimate was at $6.14 billion.

For the full-year, the company has updated earnings to reflect charges taken in the second quarter associated with customer bankruptcy filings.

Full-year adjusted earnings are expected to be in the range of $0.85 - $1.45. Sales outlook, however, remained flat with earlier guidance of $23.5 billion- $24.3 billion. Analysts see earnings of $1.3 per share on revenue of $24.13 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT